High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory H odgkin lymphoma ( HL )

Saved in:
Bibliographic Details
Published inHematological oncology Vol. 35; no. S2; p. 320
Main Authors Wannesson, B., Remaggi, G., Intile, D., Ferrari, L., Cruset, S., Fernández, I., Miodosky, M., Cugliari, M.S., Bordone, J., Pavlovsky, M.A.
Format Journal Article
LanguageEnglish
Published 01.06.2017
Online AccessGet full text

Cover

More Information
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.2439_61